COST-EFFECTIVENESS OF SECUKINUMAB AS FIRST BIOLOGIC TREATMENT FOR PSORIASIS COMPARED WITH INITIATING OTHER BIOLOGIC THERAPY IN GERMANY

Author(s)

Augustin M¹, Krieger T², McBride D², Graham CN³, Melzer N⁴, Kneidl J⁴, Neidhardt K⁴
¹University Medical Center Hamburg, Hamburg, Germany, ²RTI Health Solutions, Manchester, UK, ³RTI Health Solutions, NC, NC, USA, ⁴Novartis Pharma GmbH, Nuernberg, Germany

Presentation Documents

PSS40-augustin-m-sup-1-sup-strong-u-krieger-t-u-sup-2-sup-strong-mcbride-d-sup-2-sup-graham-cn-sup-3-sup-melzer-n-sup-4-sup-kneidl-j-sup-4-sup-neidhardt-k-sup-4-sup-br-sup-1-sup-university-medical-center-hamburg-hamburg-germany-sup-2-sup-rt ...

OBJECTIVES: In treating psoriasis, switching between biologic treatments occurs frequently. A cost-effectiveness model was adapted to assess the impact of placing secukinumab (SEC), an anti-IL-17A antibody, in treatment sequencing with other biologics: adalimumab (ADA), etanercept (ETN), infliximab (INF), and ustekinumab (UST) in eligible psoriasis patients. METHODS:

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PSS40

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Sensory System Disorders

Explore Related HEOR by Topic

Economic Evaluation

Presentation